METAL CHELATE CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DX & THERAPY

肿瘤相关单克隆抗体是潜在的治疗剂， 恶性细胞的细胞毒性剂的选择性载体。我们正在测试 这种假说在几种动物模型系统中得到证实：一种是肿瘤病毒， 另一种是人肿瘤裸鼠移植瘤， 小鼠 所使用的杀细胞剂是各种放射性核素。他们的 测定与单克隆抗体结合时的相对效力 并与单独的单克隆抗体或与 毒素选择用于研究的几种放射性核素的范围为 因此，铜-67代表了一种弱的、短的 射程，低能量β发射体，钇-90是一种射程远，高能量 β发射体，铋-212是短寿命的，α发射体和铅-212 提供短距离和长距离的β辐射和随后的α辐射 它的Bislets-212女儿。螯合剂的合成 将这些同位素连接到抗体所需的步骤现已完成。 Bi-DOTA复合物已被证明在动物模型系统中是稳定的。

Tumor-associated monoclonal antibodies are potential therapeutic agents as selective carriers of cytotoxic agents to malignant cells. We are testing this hypothesis in several animal model systems: one is a tumor virus induced leukemia of mice; another is human tumor xenographs in nude athymic mice. The cytocidal agents being employed are various radionuclides. Their relative efficacy when conjugated to monoclonal antibodies is being assayed and compared to that of monoclonal antibodies alone or conjugated to toxins. The several radionuclides chosen for study span the range of nuclidic properties available, thus Copper-67 represents a weak, short range, low energy beta emitter, Yttrium-90 is a long range, high energy beta emitter, Bismuth-212 is a short-lived, alpha emitter and Lead-212 provides both short and long range beta,emissions and the subsequent alpha emission of its Bismuth-212 daughter. The syntheses of the chelating agents required for linkage of these isotopes to antibody is now complete. The Bi-DOTA complex has been shown to be stable in an animal model system.